Tokyo, April 25 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061371) titled 'Triptans and lasmiditan in patients with migraine attacks associated with neurodevelopmental disorders' on April 24.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - University of Tsukuba, Mito Medical Center, Mito Kyodo General Hospital

Condition: Condition - patients with migraine attacks accompanied by neurodevelopmental disorders Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Triptans and lasmiditan are considered specific acute medications for migraine attacks. Despite the efficacy of these treatments, continuation of these medications was limited because some patients experienced adverse effects. A previous study reported a close association between migraine and neurodevelopmental disorders. The present study investigated triptans and lasmiditan in the treatment of consecutive patients with migraine attacks accompanied by neurodevelopmental disorders. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - Triptan and/or lasmiditan tablets were prescribed for consecutive patients after the diagnosis of migraine attacks and neurodevelopmental disorders. Triptans, eletriptan or zolmitriptan was prescribed. However, in this study, lasmiditan was used at a dose of 50 mg because the 100 mg dose led to greater adverse effects in Japanese patients.

Eligibility: Age-lower limit - Not applicable Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - All patients were diagnosed with migraine by a certified headache specialist according to the International Classification of Headache 3rd edition. For all patients, brain magnetic resonance imaging was performed, and other organic lesions causing headache were eliminated. Before this study, neurodevelopmental disorders were diagnosed by several specialists. Key exclusion criteria - Patients who could not express their headaches and the effect of the drugs. Target Size - 20

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2025 Year 01 Month 01 Day Date of IRB - 2025 Year 03 Month 26 Day Anticipated trial start date - 2025 Year 03 Month 27 Day Last follow-up date - 2026 Year 12 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070219

Disclaimer: Curated by HT Syndication.